Alpha Profiles · Company Profile

Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals.

https://registry.alpha.ac/companies/alvotech

Entity: Public listing published
Primary listing: NASDAQ: ALVO
Verification: Partially verified
Last reviewed: 2026-09-15T20:40:44.088746+00:00

Overview

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 15, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

0 public records

Board roster coverage is NOT_ASSERTED. An empty list is not evidence that this company has no board.

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-09-15T20:40:44.088746+00:00